Faculté de Médecine, INSERM U558, Toulouse, France.
Eur J Health Econ. 2011 Aug;12(4):363-71. doi: 10.1007/s10198-010-0250-6. Epub 2010 Jun 13.
Prostate cancer is an important disease in terms of economic implications because of its increasing incidence and health care costs. We assessed the direct costs of the clinical management of prostate cancer in France. A retrospective study based on population-based data was carried out. Eight hundred and seventy-nine cases of prostate cancer diagnosed in five departments were included in a 5-year follow-up study. The economic analysis adopted the health-care payer's perspective and took into account only the direct costs. The mean cost of managing patients was estimated at euro12,731. It is composed of 49 to 82% of initial treatments according to the therapeutic strategy. The follow-up constituted between 3 and 11%, the costs of treatments for side effects between 1 and 3% and the travel cost between 3 and 7%. Cumulative total costs over 5 years for each treatment group showed variation in costs. Costs were highest for patients who were treated with external-beam radiotherapy and lowest for those with watchful waiting. The cost burden of prostate cancer is high and varies according to the treatment type. This study yielded a cost analysis of the different management practices of patients with prostate cancer.
前列腺癌是一种重要的疾病，因为它的发病率和医疗保健成本不断增加。我们评估了法国前列腺癌临床管理的直接成本。这是一项基于基于人群的数据的回顾性研究。在一项为期 5 年的随访研究中，纳入了五个科室诊断出的 879 例前列腺癌病例。经济分析采用了卫生保健支付者的观点，仅考虑了直接成本。管理患者的平均费用估计为 12731 欧元。根据治疗策略，它由初始治疗的 49%至 82%组成。随访占 3%至 11%，副作用治疗费用占 1%至 3%，旅行费用占 3%至 7%。每个治疗组在 5 年内的累计总成本显示出费用的变化。接受外照射放疗的患者费用最高，而接受观察等待的患者费用最低。前列腺癌的成本负担很高，并且根据治疗类型而有所不同。本研究对前列腺癌患者的不同管理实践进行了成本分析。
